Exagen Inc. 在美国以 AVISE 品牌开发并销售基于其细胞结合补体激活产物技术的多种检测产品。该公司总部位于加利福尼亚州维斯塔。
财务指标
营业收入
2026-06-30
$1994.1万
2026-03-31
$1730.6万
2025-12-31
$1663.1万
2025-09-30
$1724.4万
营业支出
2026-06-30
$1393.9万
2026-03-31
$1361.9万
2025-12-31
$1418.1万
2025-09-30
$1317.5万
净利润
2026-06-30
-$319.6万
2026-03-31
-$396.7万
2025-12-31
-$467.3万
2025-09-30
-$708.7万
净利润率
2026-06-30
-16.02%
2026-03-31
-22.92%
2025-12-31
-28.09%
2025-09-30
-41.09%
每股收益
2026-06-30
$-0.13
2026-03-31
$-0.20
2025-12-31
$-0.26
2025-09-30
$-0.31
息税折旧摊销前利润
2026-06-30
-$136.7万
2026-03-31
-$206.5万
2025-12-31
-$273万
2025-09-30
-$515.8万
有效税率
2026-06-30
--
2026-03-31
-0.91%
2025-12-31
-0.27%
2025-09-30
-0.01%
项目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
营业收入
$1994.1万
$1730.6万
$1663.1万
$1724.4万
营业支出
$1393.9万
$1361.9万
$1418.1万
$1317.5万
净利润
-$319.6万
-$396.7万
-$467.3万
-$708.7万
净利润率
-16.02%
-22.92%
-28.09%
-41.09%
每股收益
$-0.13
$-0.20
$-0.26
$-0.31
息税折旧摊销前利润
-$136.7万
-$206.5万
-$273万
-$515.8万
有效税率
--
-0.91%
-0.27%
-0.01%
常见问题
XGN stock represents shares of common equity in its underlying company, which trades on a U.S. exchange under the ticker XGN. The stock gives investors a proportionate ownership interest in the business and its future cash flows. Its price is set by supply and demand in the market. For the current exchange listing, share class details, and latest price, refer to the XGN quote page.
The price of XGN stock moves as buyers and sellers adjust their expectations. Company-specific developments, such as earnings reports, guidance updates, or material announcements, can shift sentiment. Broader factors including sector trends, interest rates, inflation data, and overall market volatility also influence demand. Because prices update continuously during trading hours, check the live XGN quote for the most current price and recent movement.
Valuation analysis for XGN typically involves comparing its current market price with fundamental measures such as earnings, revenue, cash flow, or book value. Useful metrics may include the price-to-earnings ratio, price-to-sales ratio, and enterprise value multiples. These should be reviewed against the company's own history and against peers in its industry. The specific valuation figures for XGN are shown on the stock page and should be referenced there.
Buying XGN stock generally requires a brokerage account that offers access to U.S. equity markets. Once the account is funded, investors can place a buy order through the brokerage's platform, choosing between a market order or a limit order. Fractional shares may be available at some brokers, depending on the platform. The minimum amount depends on the broker and the current share price of XGN, which is displayed on the quote page.
Analyzing XGN's financial performance involves reviewing its quarterly and annual reports, including the income statement, balance sheet, and cash flow statement. Key metrics include revenue growth, gross and operating margins, net income, earnings per share, and free cash flow. Comparing these figures over multiple periods helps reveal trends in profitability and financial health. XGN's reported financial results can be found in its official filings and the data section of the stock page.
Investing in XGN carries risks that include market volatility, sector-specific challenges, and company-level operational or financial uncertainties. Broader economic conditions, changes in interest rates, and competitive pressures can also affect performance. Additionally, liquidity and share price fluctuations may influence how easily investors can enter or exit positions. Reviewing XGN's risk disclosures in its regulatory filings can provide more detail on the specific risks the company identifies.